- Home
- LSBK vs IKNA Comparison
LSBK vs IKNA Comparison
Compare LSBK & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- IKNA
- Stock Information
- Founded
- LSBK 1891
- IKNA 2016
- Country
- LSBK United States
- IKNA United States
- Employees
- LSBK N/A
- IKNA N/A
- Industry
- LSBK Savings Institutions
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- IKNA Health Care
- Exchange
- LSBK Nasdaq
- IKNA Nasdaq
- Market Cap
- LSBK 77.2M
- IKNA 79.6M
- IPO Year
- LSBK 2006
- IKNA 2021
- Fundamental
- Price
- LSBK $13.70
- IKNA $1.59
- Analyst Decision
- LSBK
- IKNA Buy
- Analyst Count
- LSBK 0
- IKNA 2
- Target Price
- LSBK N/A
- IKNA $3.00
- AVG Volume (30 Days)
- LSBK 955.0
- IKNA 99.7K
- Earning Date
- LSBK 01-29-2025
- IKNA 11-07-2024
- Dividend Yield
- LSBK 5.20%
- IKNA N/A
- EPS Growth
- LSBK N/A
- IKNA N/A
- EPS
- LSBK 0.74
- IKNA N/A
- Revenue
- LSBK $25,338,000.00
- IKNA $659,000.00
- Revenue This Year
- LSBK N/A
- IKNA N/A
- Revenue Next Year
- LSBK N/A
- IKNA N/A
- P/E Ratio
- LSBK $18.65
- IKNA N/A
- Revenue Growth
- LSBK N/A
- IKNA N/A
- 52 Week Low
- LSBK $10.30
- IKNA $1.22
- 52 Week High
- LSBK $14.21
- IKNA $2.30
- Technical
- Relative Strength Index (RSI)
- LSBK 62.66
- IKNA 35.62
- Support Level
- LSBK $13.44
- IKNA $1.56
- Resistance Level
- LSBK $13.67
- IKNA $1.71
- Average True Range (ATR)
- LSBK 0.02
- IKNA 0.05
- MACD
- LSBK 0.05
- IKNA -0.01
- Stochastic Oscillator
- LSBK 100.00
- IKNA 31.58
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.